Abstracts Archive - Page 1720 of 2425 - ACR Meeting Abstracts

Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…
Abstract Number: 458 • 2015 ACR/ARHP Annual Meeting
First Year Canadian Experience with Subcutaneous Abatacept in Routine Practice for the Treatment of Patients with Rheumatoid Arthritis: Data from the Orencia Response Program (ORP) Network
Boulos Haraoui¹, Louis Coupal², Radmila Day³, Lionel Budry⁴ and Youb Chalabi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ³None, Montreal, QC, Canada, ⁴Bristol Myers Squibb Canada, St-Laurent, QC, Canada, ⁵Bristol Myers Squibb, Montreal, QC, Canada
Background/Purpose: The subcutaneous (SC) formulation of abatacept (ABA) has been available in Canada since January 2014. Here we report first year experience with SC ABA…
Abstract Number: 459 • 2015 ACR/ARHP Annual Meeting
The Effect of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Positivity on Drug Survival of Abatacept in Patients with Rheumatoid Arthritis in Routine Care: The Results from Turkbio Registry
Ihsan Ertenli¹, Omer Karadag¹, Yavuz Pehlivan², Ediz Dalkilic³, Ahmet Mesut Onat⁴, Bunyamin Kisacik⁵, Gercek Can⁶, Servet Akar⁷, Sedat Capar⁸, Umut Kalyoncu¹, Mustafa Ferhat Oksuz⁹, Emine Figen Tarhan⁷ and Nurullah Akkoc⁶, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ³Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁵Rheumatology Department, Gaziantep University School of Medicine, Gaziantep, Turkey, ⁶Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey, ⁷Department of Internal Medicine, Division of Rheumatology, Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁸Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁹Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Abatacept (ABA) is a biological anti-rheumatic drug used in Rheumatoid Arthritis (RA). In TURKBIO, Turkish Biologic Registry, data on patient characteristics, diagnosis, previous treatment…
Abstract Number: 460 • 2015 ACR/ARHP Annual Meeting
Changes in Body Composition and Metabolic Profile during Treatment with Tocilizumab in Patients with Rheumatoid Arthritis
Anne Tournadre¹, Bruno Pereira², Frederic Dutheil³, Vincent Sapin⁴, Charlotte Giraud⁵, Sandrine Malochet-Guinamand⁶, Thomas Frayssac⁷, Sylvain Mathieu⁵, Jean-Jacques Dubost⁸ and Martin Soubrier⁸, ¹Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ²Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ³Preventive and Occupational Medicine, CHU G. Montpied Laboratory of Metabolic Adaptations to Exercise in Physiological and Pathological conditions EA3533, Clermont-Ferrand, France, ⁴Biochemistry and Molecular Biology Department CHU Clermont-Ferrand, Clermont Université, Université d'Auvergne, EA7281, Clermont-Ferrand, France, ⁵Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁶Rheumatology Department,, Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology, Rheumatology department CHU Clermont-Ferrand, Clermont-ferrand, France, ⁸Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis (RA) is characterized by increased cardiovascular risk and metabolic changes including cachectic obesity, insulin resistance, dyslipidemia. DMARDs decrease inflammation and could thus…
Abstract Number: 461 • 2015 ACR/ARHP Annual Meeting
Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown³, Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard⁴, Diane Sauvageau¹, Angèle Turcotte³, Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ⁴Rhumatology, Institut de recherche en rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: Very few studies have compare different agents used in the treatment of rheumatoid arthritis (RA) over the very long term. The majority of them…
Abstract Number: 462 • 2015 ACR/ARHP Annual Meeting
Radiographic Progression in Patients with Early Rheumatoid Arthritis Has Not Become Milder over the Past Decades
Carola Wassenberg¹, Rolf Rau², Siegfried Wassenberg³, Dietmar Krause⁴ and Christoph Fiehn⁵, ¹Radiology, Friedrich Ebert Krankenhaus, Neumünster, Germany, ²Expert in Rheumatology, Düsseldorf, Germany, ³Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, ⁴Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany, ⁵ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany
Background/Purpose: Retrospective studies have promoted the idea that RA has become a milder disease over the past decades[i], [ii]. These findings are questionable because of…
Abstract Number: 463 • 2015 ACR/ARHP Annual Meeting
Treatment with Biologic Agents for RA in Patients with MTX-Associated Lymphoproliferative Disorders
Takayuki Katsuyama¹, Ken-ei Sada¹, Noriko Toyota-Tatebe², Katsue S. Watanabe¹, Toru Kiguchi³ and Jun Wada², ¹Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ²Department of Medicine and Clinical Science,, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ³Department of Internal Medicine, Chugoku Central Hospital, Fukuyama, Japan
Background/Purpose: Methotrexate (MTX) is known as an anchor drug for the treatment of rheumatoid arthritis (RA), and MTX-associated lymphoproliferative disorders (MTX-LPD) is of current interest.…
Abstract Number: 464 • 2015 ACR/ARHP Annual Meeting
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Cheryl Barnabe¹, Yufei Zheng², Arto Ohinmaa², Brenda Hemmelgarn³, Gilaad Kaplan⁴, Liam Martin⁵ and Walter Maksymowych⁶, ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Institute of Health Economics, Edmonton, AB, Canada, ³Division of Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Division of Gastroenterology, University of Calgary, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada, ⁶Medicine, Medicine, University of Alberta, Edmonton, AB, Canada
Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis Background/Purpose: Aboriginal people with rheumatoid arthritis (RA) have more severe disease and an…
Abstract Number: 465 • 2015 ACR/ARHP Annual Meeting
MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort
Mami Tamai¹, Yoshikazu Nakashima¹, Kazuhiko Arima², Junko Kita¹, Masataka Umeda¹, Shoichi Fukui¹, Ayako Nishino¹, Takahisa Suzuki¹, Yoshiro Horai¹, Akitomo Okada³, Tomohiro Koga¹, Shin-ya Kawashiri^1,2, Naoki Iwamoto¹, Kunihiro Ichinose¹, Satoshi Yamasaki⁴, Hideki Nakamura¹, Tomoki Origuchi⁵, Kiyoshi Aoyagi², Masataka Uetani⁶, Katsumi Eguchi⁷ and Atsushi Kawakami¹, ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Department of Public Health, Nagasaki University, Nagasaki, Japan, ³Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁴Hiroshima University, Hiroshima, Japan, ⁵Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁶Department of Radiology and Radiation Research, Nagasaki University, Nagasaki, Japan, ⁷Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan
Background/Purpose: Given the improved detection of joint injury by MRI than by clinical examination, EULAR recommendations for the use of imaging of the joints in…
Abstract Number: 466 • 2015 ACR/ARHP Annual Meeting
Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
H.W. van Steenbergen¹, L. Mangnus², M. Reijnierse³, T. W. J. Huizinga¹ and A.H.M. van der Helm- van Mil², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Radiology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with Clinically Suspect Arthralgia (CSA) have, according to their rheumatologists, an increased risk on rheumatoid arthritis (RA), but their actual outcome is unexplored.…
Abstract Number: 467 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes of Patients with Active Rheumatoid Arthritis with Normal Acute-Phase Reactant Values
In Je Kim¹, Hyesook Park², Sang-Cheol Bae³ and Jisoo Lee⁴, ¹Division of Rheumatology, Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea, ²Dep of Preventive medicine, Ewha Womans University School of medicine, Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Internal Medicine, Ewha Womans Univeristy School of Medicine, Seoul, South Korea
Background/Purpose: Despite high clinical disease activity measured by joint counts and global assessments, some patients with active rheumatoid arthritis (RA) have normal acute-phase reactant (APR)…
Abstract Number: 468 • 2015 ACR/ARHP Annual Meeting
Clinical and Ultrasonographic Inflammation in DMARD-Naïve Early Rheumatoid Arthritis (RA) – Impact of the 2010 ACR/EULAR Classification Criteria Versus the 1987 ACR Classification Criteria
Maria K. Jonsson^1,2,3, Siri Lillegraven², Lena B. Nordberg², Anna-Birgitte Aga², Hilde B. Hammer⁴, Inge C Olsen², Bjørg-Tilde Fevang^1,5, Tore K. Kvien², Espen A. Haavardsholm² and the ARCTIC Study Group, ¹Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Clinical Science, University of Bergen, Bergen, Norway, ⁴Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: ACR and EULAR published new classification criteria for RA in 2010, aiming for early identification of patients at risk of developing persistent and erosive…
Abstract Number: 469 • 2015 ACR/ARHP Annual Meeting
Window of Opportunity to Achieve Major Outcomes in Early Rheumatoid Arthritis Patients: How Persistence with Therapy Matters
Virginia Pascual-Ramos¹ and Irazú Contreras-Yáñez², ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The window of opportunity concept states that there are superior clinical responses and the potential for remission, when patients with rheumatoid arthritis (RA) are…
Abstract Number: 470 • 2015 ACR/ARHP Annual Meeting
Disease Outcome in Patients Fulfilling the 2010 Classification Criteria for Rheumatoid Arthritis: The Impact of the Different Criteria Components
Ellen Sauar Norli^1,2, Gina Hetland Brinkmann^2,3, Tore K. Kvien², Olav Bjørneboe¹, Anne Julsrud Haugen³, Halvor Nygaard⁴, Cathrine Thunem⁵, Elisabeth Lie² and Maria Dahl Mjaavatten², ¹Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ⁴Dept. of Rheumatology, Lillehammer Hospital of Rheumatic Diseases, Lillehammer, Norway, ⁵Dept. of Rheumatology, Betanien Hospital, Skien, Norway
Background/Purpose: The 2010 ACR/EULAR classification criteria for rheumatoid arthritis (2010 RA criteria) facilitate early classification of rheumatoid arthritis (RA). The criteria yield a score ranging…
Abstract Number: 471 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Anti-Cyclic Citrullinated Peptide 2 Antibody Titer on Efficacy Outcomes Following Treatment with Subcutaneous Abatacept or Adalimumab
Jeremy Sokolove¹, M Schiff², Roy Fleischmann³, Michael Weinblatt⁴, SE Connolly⁵, A Johnsen⁵, J Zhu⁵, MA Maldonado⁵, S Patel⁵ and WH Robinson⁶, ¹Stanford University School of Medicine, Palo Alto, CA, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Bristol-Myers Squibb, Princeton, NJ, ⁶Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: In patients (pts) with RA, the predictive value of baseline (BL) titers of anti-citrullinated protein antibodies (ACPA), a known biomarker for RA and disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].